Trial Profile
An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Corticobasal degeneration; Dementia; Neurodegenerative disorders; Progressive supranuclear palsy; Tauopathies
- Focus Diagnostic use
- 20 Jul 2017 Results (n=10) related to transient equilibrium and their impact on tissue uptake ratios were presented at the Alzheimer's Association International Conference 2017
- 10 Oct 2014 New trial record